S&P 500   3,323.96 (+0.53%)
DOW   27,121.14 (+1.09%)
QQQ   270.67 (+0.11%)
AAPL   438.09 (-0.13%)
MSFT   212.65 (-0.30%)
FB   250.42 (+0.24%)
GOOGL   1,482.20 (+0.60%)
AMZN   3,187.95 (+1.56%)
NVDA   451.76 (+0.59%)
CGC   19.23 (-0.47%)
BABA   264.22 (+0.77%)
TSLA   1,482.02 (-0.33%)
MU   51.00 (-0.58%)
GE   6.15 (+0.16%)
AMD   85.69 (+0.76%)
T   29.83 (-0.60%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.25 (-2.30%)
NFLX   504.57 (-0.99%)
DIS   128.61 (+9.65%)
BAC   25.36 (+1.40%)
BA   173.15 (+4.89%)
S&P 500   3,323.96 (+0.53%)
DOW   27,121.14 (+1.09%)
QQQ   270.67 (+0.11%)
AAPL   438.09 (-0.13%)
MSFT   212.65 (-0.30%)
FB   250.42 (+0.24%)
GOOGL   1,482.20 (+0.60%)
AMZN   3,187.95 (+1.56%)
NVDA   451.76 (+0.59%)
CGC   19.23 (-0.47%)
BABA   264.22 (+0.77%)
TSLA   1,482.02 (-0.33%)
MU   51.00 (-0.58%)
GE   6.15 (+0.16%)
AMD   85.69 (+0.76%)
T   29.83 (-0.60%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.25 (-2.30%)
NFLX   504.57 (-0.99%)
DIS   128.61 (+9.65%)
BAC   25.36 (+1.40%)
BA   173.15 (+4.89%)
S&P 500   3,323.96 (+0.53%)
DOW   27,121.14 (+1.09%)
QQQ   270.67 (+0.11%)
AAPL   438.09 (-0.13%)
MSFT   212.65 (-0.30%)
FB   250.42 (+0.24%)
GOOGL   1,482.20 (+0.60%)
AMZN   3,187.95 (+1.56%)
NVDA   451.76 (+0.59%)
CGC   19.23 (-0.47%)
BABA   264.22 (+0.77%)
TSLA   1,482.02 (-0.33%)
MU   51.00 (-0.58%)
GE   6.15 (+0.16%)
AMD   85.69 (+0.76%)
T   29.83 (-0.60%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.25 (-2.30%)
NFLX   504.57 (-0.99%)
DIS   128.61 (+9.65%)
BAC   25.36 (+1.40%)
BA   173.15 (+4.89%)
S&P 500   3,323.96 (+0.53%)
DOW   27,121.14 (+1.09%)
QQQ   270.67 (+0.11%)
AAPL   438.09 (-0.13%)
MSFT   212.65 (-0.30%)
FB   250.42 (+0.24%)
GOOGL   1,482.20 (+0.60%)
AMZN   3,187.95 (+1.56%)
NVDA   451.76 (+0.59%)
CGC   19.23 (-0.47%)
BABA   264.22 (+0.77%)
TSLA   1,482.02 (-0.33%)
MU   51.00 (-0.58%)
GE   6.15 (+0.16%)
AMD   85.69 (+0.76%)
T   29.83 (-0.60%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.25 (-2.30%)
NFLX   504.57 (-0.99%)
DIS   128.61 (+9.65%)
BAC   25.36 (+1.40%)
BA   173.15 (+4.89%)
Log in

NASDAQ:APLSApellis Pharmaceuticals News Headlines

$27.05
-0.55 (-1.99 %)
(As of 08/5/2020 12:46 PM ET)
Add
Compare
Today's Range
$26.86
Now: $27.05
$27.68
50-Day Range
$25.89
MA: $30.76
$33.65
52-Week Range
$16.85
Now: $27.05
$45.04
Volume5,810 shs
Average Volume800,991 shs
Market Capitalization$2.04 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.09

Headlines

Apellis Pharmaceuticals (NASDAQ APLS) News Headlines

Source:
DateHeadline
Apellis Pharmaceuticals (NASDAQ:APLS) Rating Lowered to Sell at BidaskClubApellis Pharmaceuticals (NASDAQ:APLS) Rating Lowered to Sell at BidaskClub
marketbeat.com - July 31 at 5:23 AM
Apellis Pharmaceuticals Inc (NASDAQ:APLS) Given Consensus Recommendation of "Buy" by BrokeragesApellis Pharmaceuticals Inc (NASDAQ:APLS) Given Consensus Recommendation of "Buy" by Brokerages
americanbankingnews.com - August 4 at 2:12 AM
Apellis Pharmaceuticals (NASDAQ:APLS) Trading 7.1% Higher Apellis Pharmaceuticals (NASDAQ:APLS) Trading 7.1% Higher
americanbankingnews.com - August 3 at 8:28 PM
Apellis Pharmaceuticals (NASDAQ:APLS) Posts Quarterly  Earnings Results, Misses Expectations By $0.23 EPSApellis Pharmaceuticals (NASDAQ:APLS) Posts Quarterly Earnings Results, Misses Expectations By $0.23 EPS
www.americanbankingnews.com - August 1 at 4:17 PM
Zacks: Brokerages Anticipate Apellis Pharmaceuticals Inc (NASDAQ:APLS) to Announce -$1.30 EPSZacks: Brokerages Anticipate Apellis Pharmaceuticals Inc (NASDAQ:APLS) to Announce -$1.30 EPS
www.americanbankingnews.com - August 1 at 6:49 AM
Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Down 7.3%Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Down 7.3%
www.americanbankingnews.com - July 31 at 8:50 PM
Apellis Pharmaceuticals EPS misses by $0.23Apellis Pharmaceuticals EPS misses by $0.23
seekingalpha.com - July 31 at 7:54 AM
Apellis Pharmaceuticals (NASDAQ:APLS)  Shares Down 4% Apellis Pharmaceuticals (NASDAQ:APLS) Shares Down 4%
www.americanbankingnews.com - July 22 at 4:33 PM
Apellis Pharmaceuticals (NASDAQ:APLS) Now Covered by Analysts at Roth CapitalApellis Pharmaceuticals (NASDAQ:APLS) Now Covered by Analysts at Roth Capital
www.americanbankingnews.com - July 20 at 8:20 AM
Traders Purchase Large Volume of Apellis Pharmaceuticals Call Options (NASDAQ:APLS)Traders Purchase Large Volume of Apellis Pharmaceuticals Call Options (NASDAQ:APLS)
www.americanbankingnews.com - July 16 at 7:45 AM
Apellis advances late-stage studies of pegcetacoplan in vision loss disorderApellis advances late-stage studies of pegcetacoplan in vision loss disorder
seekingalpha.com - July 7 at 8:36 AM
Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)
finance.yahoo.com - July 7 at 8:36 AM
Apellis completes enrollment in late-stage pegcetacoplan study for rare blood disorderApellis completes enrollment in late-stage pegcetacoplan study for rare blood disorder
seekingalpha.com - July 2 at 9:38 AM
Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
finance.yahoo.com - July 2 at 9:38 AM
Hedge Funds Are Selling Apellis Pharmaceuticals, Inc. (APLS)Hedge Funds Are Selling Apellis Pharmaceuticals, Inc. (APLS)
finance.yahoo.com - June 12 at 9:52 AM
Apellis on go to file U.S. application for pegcetacoplan for rare blood disorderApellis on go to file U.S. application for pegcetacoplan for rare blood disorder
seekingalpha.com - May 21 at 10:02 AM
Apellis Announces Plans to Submit NDA for Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH)Apellis Announces Plans to Submit NDA for Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH)
finance.yahoo.com - May 21 at 10:02 AM
Apellis to Present Pivotal Paroxysmal Nocturnal Hemoglobinuria (PNH) Data at 25th EHA Annual CongressApellis to Present Pivotal Paroxysmal Nocturnal Hemoglobinuria (PNH) Data at 25th EHA Annual Congress
finance.yahoo.com - May 14 at 1:42 PM
Waltham biopharma plans new stock raise after $400M in JanuaryWaltham biopharma plans new stock raise after $400M in January
www.bizjournals.com - May 12 at 4:32 PM
Apellis launches $300M convertible debt dealApellis launches $300M convertible debt deal
seekingalpha.com - May 7 at 12:15 PM
Apellis Pharmaceuticals Announces Private Placement of Convertible Senior NotesApellis Pharmaceuticals Announces Private Placement of Convertible Senior Notes
finance.yahoo.com - May 7 at 12:15 PM
Apellis Pharmaceuticals Reports First Quarter 2020 Financial ResultsApellis Pharmaceuticals Reports First Quarter 2020 Financial Results
finance.yahoo.com - April 29 at 7:18 PM
Apellis Reports Analysis from Phase 1b Geographic Atrophy StudyApellis Reports Analysis from Phase 1b Geographic Atrophy Study
finance.yahoo.com - April 28 at 8:13 AM
venBio Closes $394 Million Life Sciences Venture Capital FundvenBio Closes $394 Million Life Sciences Venture Capital Fund
www.marketwatch.com - April 3 at 11:02 AM
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial ResultsApellis Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
finance.yahoo.com - February 27 at 5:07 PM
Apellis Pharmaceuticals Inc.Apellis Pharmaceuticals Inc.
www.barrons.com - February 20 at 10:53 PM
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase AdditionalApellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional
www.bloomberg.com - February 19 at 7:49 PM
Alexion Pharmaceuticals: Revising My ValuationAlexion Pharmaceuticals: Revising My Valuation
seekingalpha.com - February 7 at 2:46 PM
Apellis Pharmaceuticals, Inc. (APLS) vs. Hedge Fund Favorites in 2019Apellis Pharmaceuticals, Inc. (APLS) vs. Hedge Fund Favorites in 2019
finance.yahoo.com - January 13 at 3:39 PM
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional SharesApellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
finance.yahoo.com - January 13 at 3:39 PM
Apellis Pharmaceuticals Phase 3 Success, And Other News: The Good, Bad, And Ugly Of BiopharmaApellis Pharmaceuticals Phase 3 Success, And Other News: The Good, Bad, And Ugly Of Biopharma
seekingalpha.com - January 10 at 3:39 PM
Apellis Pharmaceuticals is planning to raise $350M — heres howApellis Pharmaceuticals is planning to raise $350M — here's how
www.bizjournals.com - January 9 at 10:03 PM
Apellis Pharma prices stock offering at $37; shares down 2% premarketApellis Pharma prices stock offering at $37; shares down 2% premarket
seekingalpha.com - January 9 at 5:00 PM
Biotech Stock Roundup: Updates From INCY & EXEL, APLS & LIFE Surge on Positive DataBiotech Stock Roundup: Updates From INCY & EXEL, APLS & LIFE Surge on Positive Data
finance.yahoo.com - January 8 at 4:23 PM
Publicly traded company moves HQ out of Louisville areaPublicly traded company moves HQ out of Louisville area
www.bizjournals.com - January 8 at 6:51 AM
Apellis Pharma files for mixed shelfApellis Pharma files for mixed shelf
seekingalpha.com - January 7 at 8:51 PM
Apellis Lead Drug Tops Alexions Blockbuster Soliris in a Pivotal Late-Stage StudyApellis' Lead Drug Tops Alexion's Blockbuster Soliris in a Pivotal Late-Stage Study
www.fool.com - January 7 at 3:50 PM
Heres Why Apellis Pharmaceuticals Stock Jumped as Much as 40.7% TodayHere's Why Apellis Pharmaceuticals Stock Jumped as Much as 40.7% Today
www.fool.com - January 7 at 3:50 PM
Waltham biotechs drug bests Alexions blockbuster Soliris in new trialWaltham biotech's drug bests Alexion's blockbuster Soliris in new trial
www.bizjournals.com - January 7 at 3:50 PM
Apellis Stock Soars After Head-to-Head Drug Trial Vs AlexionApellis Stock Soars After Head-to-Head Drug Trial Vs Alexion
www.barrons.com - January 7 at 3:50 PM
Apellis Pharmaceuticals Soars as Blood-Drug Test Outperforms Alexions TherapyApellis Pharmaceuticals Soars as Blood-Drug Test Outperforms Alexion's Therapy
www.thestreet.com - January 7 at 3:50 PM
Why This PNH Study Could Set the Standard for TreatmentWhy This PNH Study Could Set the Standard for Treatment
www.msn.com - January 7 at 9:54 AM
Apellis Pharmas APL-2 successful in PNH study; shares up 49% premarketApellis Pharma's APL-2 successful in PNH study; shares up 49% premarket
seekingalpha.com - January 7 at 9:54 AM
Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
finance.yahoo.com - January 7 at 9:54 AM
Apellis stock soars on positive data for potential Soliris competitorApellis stock soars on positive data for potential Soliris competitor
finance.yahoo.com - January 7 at 9:54 AM
This Biotech Just Topped Alexion's Biggest Moneymaker — And RocketedThis Biotech Just Topped Alexion's Biggest Moneymaker — And Rocketed
finance.yahoo.com - January 7 at 9:54 AM
Heres Why Apellis Pharmaceuticals Fell TodayHere's Why Apellis Pharmaceuticals Fell Today
www.fool.com - December 5 at 6:16 PM
Apellis Presents First Data on APL-2 in C3 Glomerulopathy at ASN Kidney WeekApellis Presents First Data on APL-2 in C3 Glomerulopathy at ASN Kidney Week
finance.yahoo.com - November 8 at 12:38 PM
Apellis Pharmaceuticals EPS misses by $0.09Apellis Pharmaceuticals EPS misses by $0.09
seekingalpha.com - November 5 at 7:57 AM
Apellis Pharmaceuticals Reports Third Quarter 2019 Business Update and Financial ResultsApellis Pharmaceuticals Reports Third Quarter 2019 Business Update and Financial Results
finance.yahoo.com - November 5 at 7:57 AM
Is Apellis Pharmaceuticals, Inc. (APLS) Going to Burn These Hedge Funds?Is Apellis Pharmaceuticals, Inc. (APLS) Going to Burn These Hedge Funds?
finance.yahoo.com - October 28 at 1:33 PM
This page was last updated on 8/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.